DrugPatentWatch Database Preview
Bristol Myers Squibb Company Profile
What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?
BRISTOL MYERS SQUIBB has seventy-seven approved drugs.
There are seventeen US patents protecting BRISTOL MYERS SQUIBB drugs.
There are four hundred and forty-seven patent family members on BRISTOL MYERS SQUIBB drugs in fifty-seven countries and one hundred and eighty-two supplementary protection certificates in fifteen countries.
Summary for Bristol Myers Squibb
| International Patents: | 447 |
| US Patents: | 17 |
| Tradenames: | 66 |
| Ingredients: | 58 |
| NDAs: | 77 |
| Patent Litigation for Bristol Myers Squibb: | See patent lawsuits for Bristol Myers Squibb |
Drugs and US Patents for Bristol Myers Squibb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | STILBETIN | diethylstilbestrol | TABLET, DELAYED RELEASE;ORAL | 004056-014 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bristol Myers Squibb | AMNESTROGEN | estrogens, esterified | TABLET;ORAL | 083266-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-005 | Oct 28, 2010 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bristol Myers Squibb | ZERIT | stavudine | CAPSULE;ORAL | 020412-001 | Jun 24, 1994 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-003 | Jun 28, 2006 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Bristol Myers Squibb
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | SUSTIVA | efavirenz | CAPSULE;ORAL | 020972-001 | Sep 17, 1998 | 6,939,964*PED | ➤ Sign Up |
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-003 | Oct 31, 2000 | 5,254,539*PED | ➤ Sign Up |
| Bristol Myers Squibb | ZERIT | stavudine | FOR SOLUTION;ORAL | 020413-001 | Sep 6, 1996 | 4,978,655*PED | ➤ Sign Up |
| Bristol Myers Squibb | PRAVIGARD PAC (COPACKAGED) | aspirin; pravastatin sodium | TABLET, TABLET, TABLET;ORAL | 021387-002 | Jun 24, 2003 | 5,030,447*PED | ➤ Sign Up |
| Bristol Myers Squibb | SERZONE | nefazodone hydrochloride | TABLET;ORAL | 020152-002 | Dec 22, 1994 | 5,256,664*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | ➤ Subscribe | 2004-06-01 |
| ➤ Subscribe | Capsules | 100 mg and 150 mg | ➤ Subscribe | 2010-03-19 |
| ➤ Subscribe | Tablets | 600 mg | ➤ Subscribe | 2009-04-09 |
| ➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
| ➤ Subscribe | Tablets | 2.5 mg and 5 mg | ➤ Subscribe | 2016-12-28 |
| ➤ Subscribe | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | ➤ Subscribe | 2010-06-28 |
| ➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-17 |
| ➤ Subscribe | Capsules | 300 mg | ➤ Subscribe | 2009-07-20 |
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2010-02-16 |
| ➤ Subscribe | Capsules | 50 mg, 100 mg and 200 mg | ➤ Subscribe | 2016-11-03 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-06-14 |
| ➤ Subscribe | Tablets | 30 mg | ➤ Subscribe | 2005-06-01 |
| ➤ Subscribe | Tablets | 80 mg and 140 mg | ➤ Subscribe | 2011-06-16 |
Non-Orange Book US Patents for Bristol Myers Squibb
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,189,854 | Cyclic protein tyrosine kinase inhibitors | ➤ Sign Up |
| 8,242,270 | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors | ➤ Sign Up |
| 7,960,411 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ➤ Sign Up |
| 7,338,963 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ➤ Sign Up |
| RE38629 | Solid oral dosage form comprising a combination of metformin and glibenclamide | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Bristol Myers Squibb Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2003126257 | ➤ Sign Up |
| China | 1385425 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 2006052810 | ➤ Sign Up |
| Iceland | 8803 | ➤ Sign Up |
| Israel | 177280 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Bristol Myers Squibb Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB96/049 | United Kingdom | ➤ Sign Up | PRODUCT NAME: STAVUDINE; REGISTERED: UK EU/1/96/009/001 19960508; UK EU/1/96/009/002 19960508; UK EU/1/96/009/003 19960508; UK EU/1/96/009/004 19960508; UK EU/1/96/009/005 19960508; UK EU/1/96/009/006 19960508; UK EU/1/96/009/007 19960508; UK EU/1/96/009/008 19960508; UK EU/1/96/009/009 19960508 |
| 13/034 | Ireland | ➤ Sign Up | APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001 |
| 11/024 | Ireland | ➤ Sign Up | PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923 |
| 2014000070 | Germany | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| 3 | Finland | ➤ Sign Up | |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
